Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.R. McCance, R.L. Hanson, D.J. Pettitt, P.H. Bennett, D.R. Hadden, W.C. Knowler.
Diagnosing diabetes mellitus-do we need new criteria?.
Diabetologia, 40 (1997), pp. 247-255
[2.]
National Diabetes Data Group.
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
Diabetes, 28 (1979), pp. 1039-1057
[3.]
World Health Organization.
WHO Study Group. Diabetes mellitus. Technical report series 727, OMS, (1985),
[4.]
American Diabetes Association.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care, 20 (1997), pp. 1183-1197
[5.]
Expert Workshop on Impaired Glucose Tolerance.
Diabetic Med, 13 (1996), pp. 1-31
[6.]
H.C. Gerstein, S. Yusuf.
Dysglycaemia and risk of cardiovascular disease.
Lancet, 347 (1996), pp. 949-950
[7.]
R.C. Eastman, F. Vinicor.
Science: moving us in the right direction.
Diabetes Care, 20 (1997), pp. 1057-1058
[8.]
H. King, M. Rewers.
WHO ad hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults.
Diabetes Care, 16 (1993), pp. 157-177
[9.]
M.I. Harris, K.M. Flegal, R.C. Eastman, M.S. Eberhardt, C.C. Cowie.
Comparison of diabetes diagnostic categories in the US population according to 1997 American Diabetes Association and 1980–1985 World Health Organization diagnostic criteria.
Diabetes Care, 20 (1997), pp. 1859-1862
[10.]
M.I. Harris, K.M. Flegal, C.C. Cowie, M.S. Eberhardt, D.E. Goldstein, R.R. Little, et al.
Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. The Third National Health and Nutrititon Examination Survey, 1988–1994.
Diabetes Care, 21 (1998), pp. 518
[11.]
ADA Clinical Practice Recommendations.
Position Statement. Screening for type 2 diabetes.
Diabetes Care, 21 (1998), pp. 20-22
[12.]
The DECODE Study Group.
Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data.
BMJ, 317 (1988), pp. 371-375
[13.]
The DECODE-Study Group.
Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies.
Diabetologia, 42 (1999), pp. 647-654
[14.]
R.C. Perry, A.D. Baron.
Impaired glucose tolerance. Why is it not a disease?.
Diabetes Care, 22 (1999), pp. 883-885
[15.]
I. Conget, A. Costa, E. Aguilera, M. Fernández, F. Saval, R. Gomis.
Impact of the application of new American Diabetes Association diagnostic criteria. Features of the impaired fasting glucose category.
Diabetologia, 41 (1998), pp. 3
[16.]
P.Z. Zimmet.
Diabetes epidemiology as a tool to trigger diabetes research and care.
Diabetologia, 42 (1999), pp. 499-518
[17.]
J.E. Shaw, M.P. De Courten, A.M. Hodge, D. McCarty, H. Gareboo, P. Chitson, et al.
IGT or IFG for predicting NIDDM. Who is right, WHO or ADA?.
Diabetes, 47 (1998), pp. 150
[18.]
B. Costa, J. Franch, A. Donado, J. Morató, F. Martín, J. Daniel, IGT Research Group.
Impact of the American Diabetes Association-1997 diagnosis criteria on high-risk Spanish population.
Diabetologia, 41 (1998), pp. 122
[20.]
W.C. Knowler, K.M.V. Narayan, R.L. Hanson, R.G. Nelson, P.H. Bennet, J. Tuomilehto, et al.
Preventing non-insulin-dependent diabetes.
Diabetes, 44 (1995), pp. 483-488
[21.]
M. Harris.
Impaired glucose tolerance in the US population.
Diabetes Care, 12 (1989), pp. 464-474
[22.]
D.C. Brown, C.D. Byrne, P.M.S. Clark, L. Cox, N.E. Day, C.N. Hales, et al.
Height and glucose tolerance in adult subjects.
Diabetologia, 34 (1991), pp. 531-533
[23.]
J. Bayo, C. Sola, F. García, P.M. Latorre, J.A. Vázquez.
Prevalencia de la diabetes mellitus no dependiente de la insulina en Lejona (Vizcaya).
Med Clin (Barc), 101 (1993), pp. 609-612
[24.]
J. Franch, J.C. Álvarez, F. Álvarez, F. Diego, R. Hernández, A. Cueto.
Epidemiología de la diabetes mellitus en la provincia de León.
Med Clin (Barc), 98 (1992), pp. 607-611
[25.]
C. Castell, R. Tresserras, A. Goday, N. De Lara, J. Serra, G. Lloveras.
Prevalencia de diabetes mellitus no insulinodependiente en Cataluña.
Av Diabetol, 12 (1996), pp. 18
[26.]
B. Costa, J. Monclús, J.L. Llor, D. Gellida, G. García, I. Cugat, el Grup per a l’Estudi de la Diabetis a Tarragona.
Diabetes y transtornos ignorados de la tolerancia a la glucosa en atención primaria. Evidencia mediante detección oportunista.
Aten Primaria, 16 (1995), pp. 532-537
[27.]
B. Costa, F. Martín, A. Donado, I. Ricart, R. Pedret, J. Daniel, el Grupo de Investigación sobre Intolerancia a la Glucosa.
Detección selectiva de into-lerancia a la glucosa y diabetes en atención primaria. El Estudio ITGReus (Tarragona).
Aten Primaria, 22 (1998), pp. 71-78
[28.]
B. Costa, J. Franch, F. Martín, J. Morató, A. Donado, J. Basora, IGT Research Group, et al.
Impact of the American Diabetes Association diagnosis criteria on high-risk Spanish population.
Diab Res Clin Pract, 46 (1999), pp. 75-81
[29.]
B. Costa, F. Martín, A. Donado, F. Parera, J.L. Piñol, J. Basora, el Grupo de Investigación ITG (Reus-Tarragona).
Diabetes ignorada y otras alteraciones del metabolismo glucídico en la población española de alto riesgo. El Estudio ITG.
Med Clin (Barc), 114 (2000), pp. 601-608
[30.]
R. Temple, P.M.S. Clark, C.N. Hales.
Measurement of insulin secretion in type 2 diabetes: problems and pitfalls.
Diabet Med, 9 (1992), pp. 503-512
[31.]
E. Ferrannini, S.M. Haffner, B.D. Mitchell, M.P. Stern.
Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome.
Diabetologia, 34 (1991), pp. 416-422
[32.]
R.A. Sicree, P.Z. Zimmet, H.O.M. King, J.S. Coventry.
Plasma insulin response among Nauruans, prediction of deterioration in glucose tolerance over 6 yr.
Diabetes, 36 (1987), pp. 179-186
[33.]
M.J. Davies, G. Rayman, A. Grenfell, I.P. Gray, J.L. Day, C.N. Hales.
Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolereance.
Diabetic Med, 11 (1994), pp. 432-436
[34.]
W. Pimenta, M. Korytkowski, A. Mitrakou, T. Jenssen, H. Yki-Jarvinen, W. Evron, et al.
Pancreatic beta-cell dys-function as rhe primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.
JAMA, 273 (1995), pp. 1855-1861
[35.]
S.E. Kahn, D.L. Leonetti, R.L. Prigeon, E.J. Boyko, R.W. Bergstrom, W.Y. Fujimoto.
Proinsulin as a marker for the development of NIDDM in Japanese-American men.
Diabetes, 44 (1995), pp. 173-179
[36.]
R.J. Heine, G. Nijpels, J.M. Mooy.
New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors.
Diabetic Med, 13 (1996), pp. 12-14
[37.]
H. Keen, R.J. Jarret, P. McCartney.
The ten- year follow up of the Bedford survey (1962–1972); glucose tolerance and diabetes.
Diabetologia, 22 (1982), pp. 73-78
[38.]
J.M. Mooy, P.A. Grootenhuis, H. De Vries, H. Valkenburg, L.M. Bouter, P.J. Kostense, et al.
Prevalence and determinants of glucose intolerance in a Dutch caucasian population: The Hoorn Study.
Diabetes Care, 18 (1995), pp. 1270-1273
[39.]
T. Kadowaki, Y. Miyake, R. Hagura, Y. Akanuma, H. Kajinuma, N. Kuzuya, et al.
Risk factors for worsenig to diabetes in subjects with impaired glucose tolerance.
Diabetologia, 26 (1984), pp. 44-49
[40.]
H. King, M. Rewers.
WHO ad hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults.
Diabetes Care, 16 (1993), pp. 157-177
[41.]
M.F. Saad, W.C. Knowler, D.J. Pettitt, R.J. Nelson, P.H. Bennet.
Transient impaired glucose tolerance in Pima indians: is it important?.
BMJ, 297 (1988), pp. 1438-1440
[42.]
R.R. Little, J.D. England, H.M. Wiedmeyer, R.W. Madsen, D.J. Pettit, W.C. Knowler, et al.
Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance.
Diabetologia, 37 (1994), pp. 252-256
[43.]
D. Pettitt, W. Knowler, J. Lisse, P. Bennet.
Development of retinopathy and proteinuria in relation to plasma-glucose concentrations in Pima Indians.
Lancet, II (1980), pp. 1050-1052
[44.]
M.A. Charles, A. Fontbonne, N. Thibult, J.M. Warner, G.E. Rosselin, E. Eschwege.
Risk factors for NIDDM in white population.
Diabetes, 40 (1991), pp. 796-799
[45.]
N. Unwin, K.G.M.M. Alberti, R. Bhopal, J. Harland, W. Watson, M. White.
Comparison of the current WHO and new ADA criteria for the diagnosis of diabetes mellitus in three ethnic groups in the UK.
Diabet Med, 15 (1998), pp. 554-557
[46.]
S.F. Dinneen, D. Maldonado, C.L. Leibson, G.G. Klee, H. Li, L.J. Melton, et al.
Effects of changing diagnostic criteria on the risk of developing diabetes.
Diabetes Care, 21 (1998), pp. 1408-1413
[47.]
O. Vaccaro, G. Ruffa, A.A. Rivellese, G. Ricardi.
Clinical significance of the new diagnostic category of IFG. A prospective analysis.
Diabetologia, (1998),
[48.]
O. Vaccaro, G. Ruffa, G. Imperatore, V. Iovino, G. Riccardi.
Risk of diabetes in the new diagnostic category of IFG: a prospective analysis.
Diabetes, (1999),
[49.]
J.A. Vázquez, S. Gaztambide, E. Soto-Pedre.
Estudio prospectivo a 10 años sobre la incidencia y factores de riesgo de diabetes mellitus tipo 2.
Med Clin (Barc), 115 (2000), pp. 534-539
[50.]
R.C. Perry, A.D. Baron.
Impaired glucose tolerance. Why is it not a disease?.
Diabetes Care, 22 (1999), pp. 883-885
[51.]
S.E. Moss, R. Klein, B.E.K. Klein, S.M. Meuer.
The association of glycemia and cause-specific mortality in diabetic population.
Arch Intern Med, 154 (1994), pp. 2473-2479
[52.]
D.L. Wingard, C. Scheidt-Nave, E.L. Barret-Connor, J.B. McPhillips.
Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM.
Diabetes Care, 16 (1993), pp. 1022-1025
[53.]
Y. Yamasaki, R. Kawamori, H. Matsushima, H. Nishizawa, M. Kodama, M. Kubota, et al.
Asymptomatic hyperglycemia is associated with increased intimal plus medial thickness of the carotid artery.
Diabetologia, 38 (1995), pp. 585-591
[54.]
B. Balkau, M. Shipley, R.J. Jarret, K. Pyorala, M. Pyorala, A. Forhan, et al.
High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men.
Diabetes Care, 21 (1998), pp. 360-367
[55.]
M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, A. Sekikawa.
Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study.
Diabetes Care, 22 (1999), pp. 920-924
[56.]
B. Costa, J. Franch, F. Martín, J. Morató, A. Donado, J. Basora, IGT Research Group, et al.
Cardiovascular risk related to WHO/ADA diagnostic categories on high risk spanish population.
Diabetologia, 42 (1999), pp. 110
[57.]
J.A. Scarlet, R.S. Gray, J. Griffin, J.M. Olefsky, O.G. Kolterman.
Insulin treatment reverses the insulin resistance of type II diabetes mellitus.
Diabetes Care, 5 (1982), pp. 353-363
[58.]
X. Pan, G. Li, Y. Hu, J.X. Wang, W.Y. Yang, Z.X. An, et al.
Effect of diet and exercice in preventing NIDDM in people with impaired glucose tolerance: The Da Quing IGT and Diabetes Study.
Diabetes Care, 20 (1997), pp. 537-544
[59.]
J. Tuomilehto, J. Lindstrom, J.G. Eriksson, T.T. Valle, H. Hamalainen, P. Ilanne-Parikka, et al.
Prevention o type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
N Engl J Med, 344 (2001), pp. 1343-1350
[60.]
R.P. Donahue, R.D. Abbot, D.M. Reed, K. Yano.
Postchallenge glucose concentrations and coronary hearth disease in men of Japanese ancestry: Honolulu heart program.
Diabetes, 36 (1987), pp. 689-692
[61.]
B. Costa, J.M. Hernández, T. Basora, J.L. Piñol, el Grupo de Investigación ITG.
Incidencia de diabetes en la población española de mayor riesgo.
Med Clin (Barc), (2001),
[62.]
B. Costa, J. Arroyo, À. Sabaté.
The economics of pharmacotherapy for diabetes mellitus.
PharmacoEconomics, 11 (1997), pp. 139-158
[63.]
G. Sartor, B. Scherten, S. Carlström, A. Melander, G. Persson.
Ten years follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation.
Diabetes, 29 (1980), pp. 41-49
[64.]
S. Karunakaran, M.S. Hammersley, R.J. Morris, R.C. Turner, R.R. Holman.
The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Metabolism, 46 (1997), pp. 56-60
[65.]
R.J. Jarret, H. Keen, J.H. Fuller, M. Mc-Cartney.
Worsenig to diabetes in men with impaired glucose tolerance («borderline diabetes»).
Diabetologia, 16 (1979), pp. 25-30
[66.]
A.J. Scheen, M.R. Letiexhe, P.J. Lefebvre.
Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.
Diabet Med, 12 (1995), pp. 985-989
[67.]
J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, J. Olefsky.
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
N Eng J Med, (1994), pp. 1188-1193
[68.]
K. Mimura, F. Umeda, S. Hiramatsu, S. Taniguchi, Y. Ono, N. Nakashima, et al.
Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.
Diabet Med, 11 (1994), pp. 685-691
[69.]
J.L. Chiasson, R.G. Josse, L.A. Leiter, M. Mihic, D.M. Nathan, C. Palmason, et al.
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Diabetes Care, 19 (1996), pp. 1190-1193
[70.]
J.L. Chiasson, R. Gomis, M. Hanefeld, R.G. Josse, A. Karasik, M. Laakso.
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Diabetes Care, 21 (1998), pp. 1720-1725
[71.]
A. Calle, J. García, P.J. Martín, J.R. Calle, J.P. Marañes.
Influence of 16-weeks monotherapy with acarbose on cardiovascular risk factors in obese subjects with NIDDM: a controlled, double-blind comparison study with placebo.
Diabetes & Metabolism (Paris), 22 (1996), pp. 201-202
[72.]
B. Costa, C. Piñol, A. Cobos, A. Donado, F. Martín, el Grupo de Investigación PREDIAP.
Prevención de la diabetes en atención primaria (PREDIAP). Primer ensayo clínico multicéntrico español de intervención farmacológica en situación prediabética.
Av Diabetol, 16 (2000), pp. 10
[73.]
W.M. Hart, C. Espinosa, J. Rovira.
Costs of known diabetes mellitus in Spain.
Med Clin (Barc), 109 (1997), pp. 289-293
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
